Adressing complicated pregnancies, iPremom raises €15 million to advance early detection

iPremom, a Spanish molecular diagnostics company addressing the early identification of pregnancy complications, has raised €15 million in Seed funding to support clinical validation and the commercial rollout of its MaiRa platform, which analyses early signals of first-trimester pregnancy complications through blood tests.

The round was led by Amadeus Capital Partners, with participation from Asabys Partners and APEX Ventures.

Professor Carlos Simón, co-founder and Chairman of iPremom, says: “Pregnancy complications have been under-diagnosed and under-treated for generations, because the field was looking in the wrong place at the wrong time. Our ambition is not just to build a better preeclampsia test, it is to give every pregnant woman a comprehensive, early molecular picture of her pregnancy. This funding is a critical step toward making that a clinical reality.”

iPremom’s Seed round comes amid a relatively busy European investment flow in molecular diagnostics, women’s health and earlier disease detection in 2026.

EU-Startups has reported approximately €35.8 million across a selected group of adjacent financings this year, including €5 million for Paris-based En Carta Diagnostics’ at-home molecular testing platform, €1.1 million for Germany’s Intu Diagnostics, whose first application focuses on HPV testing in women’s health, €1.7 million for Zurich-based KOVE Medical to reduce preterm-birth risks following foetal surgery, and €5.2 million for menstrual-health company DITTO.

AI- and biomarker-led diagnostics have also attracted capital, including €2.8 million for Moonlight AI and €17.1 million for preventive-health platform Lucis.

In Spain, Barcelona-based Health Lean Analytics has raised more than €2.1 million for hospital-focused HealthTech – marking the closest peer in Spain for iPremom.

Pierre Socha, Partner at Amadeus Capital Partners, adds: “We are delighted to partner again with Prof. Simón, after the success of Igenomix which transformed IVF genetics. iPremom is poised to do the same for prenatal care, an even larger market opportunity. By predicting risk from the first weeks of pregnancy based on a simple blood test, it will inform and prepare millions of expecting couples, arm clinicians with unparalleled insights for targeted intervention, and give every baby the best possible start in life. We are proud to be leading this round.”

Founded in 2019, iPremom is a MedTech company based in Valencia, Spain dedicated to the early prediction and prevention of pregnancy complications through molecular diagnostics and AI-based predictive models.

iPremom’s MaiRa platform is built on more than a decade of research by co-founders Professor Carlos Simón, MD, PhD, Chairman of iPremom, and Dr. Tamara Garrido, Chief Scientific Officer. Their work shows that the molecular signals linked to pregnancy complications can be detected in maternal blood from the first trimester, well before clinical symptoms appear.

In preeclampsia, for example, this is linked to decidualisation resistance, where the uterine lining does not develop as expected, leaving a detectable cell-free RNA (cfRNA) signal in the blood as early as 9 to 14 weeks into the pregnancy.

Using a single blood sample, clinicians can use MaiRa to analyse cfRNA and use predictive modelling to assess risk across a range of pregnancy complications, such as preeclampsia, months before symptoms appear.

The platform has been developed using real-life patient data from more than 26,000 samples, linked to 10,000 pregnancies that were part of the PREMOM study, one of Spain’s largest prospective clinical trials. This dataset is also already supporting the identification of molecular signals linked to a broader set of complications, which will be added to the platform over time.

According to data provided by the company, pregnancy complications remain a major challenge for families and health systems worldwide, claiming 260,000 maternal lives, nearly 2 million babies stillborn at 28 weeks or more of gestation, and 2.3 million children in the first month of life annually.

Preeclampsia alone now affects 5 to 8% of all pregnancies globally, while pre-term birth, foetal growth restriction, and gestational diabetes place further strain on families and health systems. Despite this, iPremom believes that current diagnostic tools often identify risks only after complications have already begun to develop.

The company is now preparing for further regulatory approvals in the EU and USA.

The post Adressing complicated pregnancies, iPremom raises €15 million to advance early detection appeared first on EU-Startups.